CONCORDBIO

Concord Biotech Limited

Source: NSE · Updated 4 Nov, 06:28 pm IST

Filed 27 Oct, 07:11 pm IST Q2 FY27 (Sep ’26)Consolidated₹ lakhs

Revenue

30,907.02

▲ 25.1% vs Q2 FY26

Operating profit (EBITDA, derived from filing)

10,438.01

▲ 18.0% vs Q2 FY26

Net profit

6,957.2

▲ 10.3% vs Q2 FY26

EPS (₹)

6.65

▲ 10.3% vs Q2 FY26

Operating margin

33.8%

−200 bps vs Q2 FY26

Net margin

22.5%

−300 bps vs Q2 FY26

Revenue up, profit up vs Q2 FY26

Revenue+25% vs Q2 FY26 · +20% vs Q1 FY27

Profit+10% vs Q2 FY26 · +21% vs Q1 FY27

View official filing ↗

Numbers from the company's structured XBRL filing on NSE, cross-checked with P&L totals.

Previous-quarter and year-ago figures: as originally reported in those quarters' NSE filings; filing PDF not available to confirm restatements.

Quarter comparison

Item	Q2 FY27 (Sep ’26)	Q1 FY27 (Jun ’26)	vs Q1 FY27	Q2 FY26 (Sep ’25)	vs Q2 FY26
Revenue from operations	30,907.02	25,748.9	▲ 20.0%	24,705.75	▲ 25.1%
Other income	1,016.93	1,282.59	▼ 20.7%	1,335.21	▼ 23.8%
Total income	31,923.95	27,031.49	▲ 18.1%	26,040.96	▲ 22.6%
Total expenses	22,310.03	19,324.91	▲ 15.4%	17,701.7	▲ 26.0%
Operating profit (EBITDA)*	10,438.01	8,237.58	▲ 26.7%	8,849.11	▲ 18.0%
Profit before tax	9,613.92	7,706.58	▲ 24.7%	8,339.26	▲ 15.3%
Tax expense	2,590.84	2,064.62	▲ 25.5%	2,262.12	▲ 14.5%
Net profit	6,957.2	5,769.69	▲ 20.6%	6,306.28	▲ 10.3%
EPS (₹)	6.65	5.52	▲ 20.5%	6.03	▲ 10.3%
Operating margin	33.8%	32.0%	+180 bps	35.8%	−200 bps
Net margin	22.5%	22.4%	+10 bps	25.5%	−300 bps

Showing Q2 FY27 (Sep ’26) and change vs Q2 FY26. Turn your phone sideways for Q1 FY27 (Jun ’26).

Figures in ₹ lakhs except EPS. Consolidated figures from the company's XBRL filing on NSE. Each row is shown only if it reconciles with the others (e.g. PBT − tax = net profit); rows we couldn't verify are left out. Net margin = net profit ÷ revenue. *Operating profit (EBITDA), derived from the filing: profit before exceptional items and tax + finance costs + depreciation − other income. Operating margin = EBITDA ÷ revenue.

All Concord Biotech results, dividends & filings ›

Other results filed 27 Oct

ROUTE ROUTE MOBILE LIMITED›VISL Vedanta Iron and Steel Limited›INDIAMART Indiamart Intermesh Limited›UNIMECH Unimech Aerospace and Manufacturing Limited›LTFOODS LT Foods Limited›QUICKHEAL Quick Heal Technologies Limited›KNACK Knack Packaging Limited›UBL United Breweries Limited›STARHEALTH Star Health and Allied Insurance Company Limited›CGCL Capri Global Capital Limited›SYNGENE Syngene International Limited›CENTENKA Century Enka Limited›

Today's results ›

CONCORD BIOTECH Q2 FY27 ; NET PROFIT UP 10% AT ₹70 CR (YOY), UP 21% (QOQ)

REVENUE UP 25% AT ₹309 CR (YOY), UP 20% (QOQ)

EBITDA UP 18% AT ₹104 CR (YOY), UP 27% (QOQ)

MARGINS AT 33.8% VS 35.8% (YOY), 32.0% (QOQ)

https://resultkal.com/r/concordbio-2026-10-27
Source: NSE filing · not investment advice

FAQ

When did Concord Biotech announce Q2 FY27 results?

Concord Biotech filed its results on NSE on 27 Oct, 07:11 pm IST.

What does QoQ and YoY mean?

QoQ compares with the previous quarter; YoY compares with the same quarter last year. Growth is calculated from the figures in the filing.

Are these Concord Biotech figures official?

They are auto-read from the company's NSE filing and may contain errors. Always confirm with the official PDF linked on this page.

Explore

Today's results Results this week Q2 FY27 results dates Dividend stocks this week Bonus issue 2026 Stock split 2026

Figures are auto-read from the company's NSE filing and may contain errors. Check the official filing before deciding. Not investment advice.

← CONCORDBIO overview